Despite recent advances in drug development, autologous stem cell transplant (ASCT) is still, to date, the most effective treatment for…
Abstracts are often the most informative parts of scientific publications, as they contain a complete overview of the entire paper.…
While daratumumab is one of the most effective treatments for multiple myeloma (MM), ~50% of all patients who the drug…
Autologous stem cell transplantation (ASCT) for multiple myeloma (MM) patients has often been capped at 65 years of age. However,…
Autologous stem cell transplantation is here to stay for multiple myeloma (MM). However, once a treatment has been developed, there…
Measurable residual disease (MRD) status is a valuable prognostic marker in multiple myeloma (MM), but questions still remain. Speaking from…
Measurable residual disease (MRD) is evaluated and analyzed in clinical trials, but less attention is currently given to it in…
Elderly patients with multiple myeloma (MM) are often denied intensive treatment due to the fear they will not be able…
Measurable residual disease (MRD) can be determined using a variety of techniques. However, the majority of trials perform bone marrow…
While it is understandable that elderly patients with multiple myeloma (MM) are generally excluded from more aggressive treatments, Mohamad Mohty,…
Noa Biran, MD, discusses her thoughts on the promising combination of carfilzomib and daratumumab in revlimid-refractory multiple myeloma patients at…
David I. Quinn, MD,the trade-offs between safety and efficacy in 1st line renal cell carcinoma (RCC) treatment options at the…
Neelima Denduluri, MD, talks about how to differentiate CDK4/6 inhibitors and whether they be used interchangeably
Primo N. Lara, Jr., MD, explains the trade-offs between safety and efficacy when considering 1st line renal cell carcinoma (RCC)…
Eunice Wang, MD, talks about some of the evolving treatment considerations for FLT3 mutated acute myeloid leukemia (AML) patients who…
Noa Biran, MD, talks about her thoughts on the promising combination of carfilzomib and daratumumab in revlimid-refractory multiple myeloma patients…
David I. Quinn, MD, discusses whether the convenience factor of oral TKIs enters into the decision-making process when treating advanced…
Lisa Rometty, Vice President and General Manager, Oncology, Life Sciences, and Personal Health, IBM Watson Health, talks about how augmented…
Douglas W. Blayney, MD, explains differentiating CDK4/6 Inhibitors and if they can be used interchangeably.
Neelima Denduluri, MD, shares her thoughts on the practice-changing results of the TAILORx study presented at the 2018 Annual Meeting.
Primo N. Lara, Jr., MD, explains how a newly diagnosed advanced renal cell carcinoma (RCC) patient should be treated in…
Howard Hochster, MD, shares his perspective on the outcomes of the PRODIGY7 study in metastatic colorectal cancer patients using heated…
Eunice Wang, MD, talks about what we’ve learned about gilteritinib in FLT3-ITD mutated acute myeloid leukemia (AML) patients at the…
David I. Quinn, MD, explains his thoughts on 2nd line therapy options following I-O failure 2018 Annual Meeting.
Neelima Denduluri, MD, shares her thoughts on the implications of the TAILORx study at the 2018 Annual Meeting.
Noa Biran, MD, talks about her thoughts on the logistics involved in delivering CAR-T in the BB2121 study in multiple…
Patients with advanced chronic lymphocytic leukemia (CLL) don’t respond well to chimeric antigen receptor (CAR) T-cell therapy. In this interview,…
The British Society for Haematology (BSH) 2018 Annual Meeting in Liverpool, UK, had a record number of clinical experts in…
The UK is in a leading position internationally for use of minimal residual disease (MRD) measurements in acute myeloid leukemia…
Chris Fegan, MB, MD, FRCP, FRCPath, from Cardiff University, Cardiff, UK, touches on several of the national and international cohort…
There are three times more patients with sickle cell disease (SCD) than cystic fibrosis (CF) in the USA, yet SCD…
BTK inhibitors have seen success in treating various hematological malignancies, and their approval has been extended to mantle cell lymphoma…
Richard Dillon, MBBS, from King’s College London, UK, discusses the current landscape for minimal residual disease (MRD) in acute myeloid…
Telomere erosion and fusion play an important role in the pathology of many common human malignancies, including chronic lymphocytic leukemia…
Could patients who remain MRD negative long-term whilst on maintenance treatment cease treatment? Here, Ola Landgren, MD, PhD, from Memorial…
There are many questions surrounding minimal residual disease (MRD) detection and its role in decision making; for example, whether drug…
Timothy Hughes, MD, of the Royal Adelaide Hospital, Adelaide, Australia, talks about the TARGET survey, a survey of real-world management…
Ola Landgren, MD, PhD, from Memorial Sloan Kettering Cancer Center, NY, describes novel uses for minimal residual disease (MRD) measurement…
Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, discusses an exciting preclinical investigation of the…
Treatments for multiple myeloma (MM) in newly diagnosed and relapsed patients differ between regions, particularly with the rapid advancements in…
Timothy Hughes, MD, of the Royal Adelaide Hospital, Adelaide, Australia, gives us an overview of the follow-up study of ENESTcmr.…
Ramon Garcia-Sanz, MD, PhD from the University Hospital of Salamanca, Salamanca, Spain, shares exciting data in Waldenströms macroglobulinemia (WM) from…
Very soon, minimal residual disease (MRD) testing will become a routine part of clinical practice. Therefore, it is important that…
Previous clinical trial investigations have established that daratumumab plus bortezomib, melphalan and prednisone, also known as dara+VMP, is significantly more…
Newer treatments for hematological malignancies, including immunotherapies and cellular therapies, are more targeted than historical chemotherapies. This means that the…
The current treatment landscape of CML is at a very exciting time. Here, Timothy Hughes, MD, of the Royal Adelaide…
The combination of brentuximab vedotin and ESHAP has had positive results when used prior to autologous stem cell transplant in…
The measurement and use of minimal residual disease (MRD) is an exciting development in the world of hematological oncology. So,…
The 23rd congress of the European Haematology Association (EHA) 2018, held in Stockholm, Sweden, presented exciting data from multiple myeloma…
A small proportion (~20%) of multiple myeloma (MM) patients are at a high risk of relapse and aggressive disease progression.…
CAR T-cells are gaining traction as a therapy for a variety of hematological malignancies. Here, Oliver Ottmann, MD, FRCPath, of…
Daratumumab is one of the most promising new therapies in multiple myeloma (MM). Here, Matthew Jenner, MBBS, MRCP, FRCPath, PhD,…
Lenalidomide monotherapy has proven to be an effective maintenance treatment for multiple myeloma (MM). Matthew Jenner, MBBS, MRCP, FRCPath, PhD,…
To determine the true impact of ibrutinib treatment in patients with chronic lymphocytic leukemia (CLL) within a population-based setting rather…
Venetoclax is making headlines due to its effectiveness against many hematological cancers. In this video, Giovanni Martinelli, MD, of the…
Stem cell transplants are one of the most well-studied and effective therapies for blood cancers. In this video, Anna Sureda,…
John Leighton, MD, shares his thoughts on the headline Immunotherapy Now Standard for Some Patients With Colorectal Cancer
Atrayee Basu Mallick, MD, shares the advances in the treatment of colorectal cancer
Primo N. Lara, Jr., MD, explains how he decides which metastatic renal cell carcinoma (mRCC) patients should receive a TKI…
Howard Hochster, MD, weighs in on the VALENTINO study regarding the effectiveness of maintenance 5FU/LV following FOLFOX + panitumumab induction…
Eunice Wang, MD, shares the potential impact of gilteritinib as maintenance therapy after allogenic hematopoietic stem cell transplantation in patients…
David I. Quinn, MD, talks about which metastatic RCC patients should receive a TKI as first-line therapy.
John Leighton, MD, explains shares the results of the PREOPANC-1 study and, resectable pancreatic cancer patients should recieve preoperative chemotherapy…
Mark Levis, MD, PhD, weighs in on the evolving treatment considerations for FLT3 mutated acute myeloid leukemia (AML) patients who…
Randall A. Oyer, MD, Dr. Oyer explains how ACCC is contributing to the work being done to address disparities in…
Noa Biran, MD, discusses the impact of the BB2121 study in multiple myeloma patients and how the results compare to…
David I. Quinn, MD, explains discusses Keynote 427 for Pembrolizumab, PD-1 Inhibitor and CTLA4 with Nivolumab & Ipilimumab presented at…
Atrayee Basu Mallick, MD, talks about how tumor-sidedness impacts her colorectal cancer (CRC) treatment algorithms at Annual Meeting 2018.
Mark Levis, MD, PhD, shares his thoughts on the most exciting clinical trial data coming out of the 2018 Annual…
Primo N. Lara, Jr., MD, explains how how checkpoint inhibitors figure into treatment algorithms for unresectable 1st line renal cell…
Howard Hochster, MD, explains the outcomes of the ECOG-7208 study in 2nd line metastatic colorectal cancer (mCRC) patients at Annual…
Eunice Wang, MD, talks about the impact of next-generation sequencing on treatment selection in acute myeloid leukemia (AML) at Annual…
Noa Biran, MD, shares her opinion on the most exciting clinical data presented at the 2018 Annual Meeting Annual Meeting.
David I. Quinn, MD, shares his thoughts on the most interesting renal cell carcinoma (RCC) data being presented at the…
After presenting the initial results of a study investigating the efficacy of ibrutinib for chronic lymphocytic leukemia (CLL) within a…
Cancerous cells in acute myeloid leukemia (AML) utilize different metabolic pathways to normal cells. Using this difference in their biology,…
Trends in the use of stem cell transplantation in relapsed and refractory Hodgkin lymphoma are currently being studied by the…
The 23rd Congress of the European Hematological Association (EHA) 2018 in Stockholm, Sweden, saw many researchers presenting the newest data…
Since its approval in late 2014, ibrutinib has primarily been studied in clinical trials, such as RESONATE (NCT01578707), and in…
The treatment of acute myeloid leukemia (AML) patients who have relapsed has, to date, been quite difficult as there has…
While the current frontline ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regimen for treating advanced-stage Hodgkin lymphoma is effective with manageable side…
Acute lymphoblastic leukemia (ALL) is currently treated with a regimen of drugs that, while effective to an extent, could be…
The purpose of the iNNOVATE study (NCT02165397) was to evaluate the safety and efficacy of ibrutinib and rituximab for the…
Pomalidomide combinations in randomized trials are generating exciting data for relapsed/refractory multiple myeloma (MM). Here, Meletios Dimopoulos, MD, from the…
Dr Laurie Sehn, of the BC Cancer Agency, Vancouver, BC, Canada presents: ‘Answering the unmet need in one of the…
Gareth Morgan, MD, PhD, FRCP, FRCPath, from the University of Arkansas for Medical Sciences, Little Rock, AR, gives a brief…
Novel strategies are required to move from simply controlling multiple myeloma (MM), to overcoming it and acheiving long-term remissions in…
Bruno Paiva, PhD, from the University of Navarra, Navarra, Spain, shares insights into multiple myeloma (MM) from the 23rd congress…
Barbara Eichhorst, MD, from Uniklink Koln, Koln, Germany discusses the results of the recent Phase III CLL11 trial (NCT01998880). The…
Barbara Eichhorst, MD, from Uniklink Koln, Koln, Germany, talks to us about exciting new data for the venetoclax and rituximab…
In this interview with Arjan Diepstra, PhD, from the University of Groningen, Groningen, Netherlands, speaking from the 23rd congress of…
Treatment of myeloproliferative neoplasms (MPNs) is expanding to include several exciting new therapies. We spoke to Claire Harrison, MD, FRCP,…
Measurable residual disease (MRD) has become a crucial part of treatment planning and prognosis construction in many hematological diseases; however,…
Treating young patients with chronic lymphocytic leukemia (CLL) poses a unique set of challenges because treatment has to be effective…
Claire Harrison, MD, FRCP, FRCPath, from Guy’s and St Thomas’ Hospital, London, UK, presented updates and results from the MAJIC…
Allogenic stem cell transplants are the only curative therapy available for several hematological diseases; however, graft-versus-host disease (GvHD) is a…
Chronic lymphocytic leukemia (CLL) treatment is experiencing a shift away from chemotherapy in favor of novel agents. FCR chemotherapy, however,…
Treating myelofibrosis is accompanied by several complications that must be considered, including thrombocytopenia and anemia. In this video, recorded at…
Nicholas J. Vogelzang, MD, shares his thoughts on imaging as an effective solution for prostate cancer diagnosis at Annual Meeting…
Atrayee Basu Mallick, MD, shares how nivolumab is being incorporated into metastatic colorectal cancer (mCRC) treatment algorithms at Annual Meeting…
Randall A. Oyer, MD, explains the immunotherapy data coming out of the Annual Meeting 2018 and the purpose of the…
Mark Levis, MD, PhD, talks about new information about gilteritinib in FLT3 mutated acute myeloid leukemia (AML) at Annual Meeting…
John Leighton, MD, explains whether tumor sidedness impacts colorectal cancer treatment algorithms at Annual Meeting 2018.
Ivo Abraham, PhD, RN, shares his thoughts on demonstrating the value of cancer care in today’s oncology landscape at Annual…
Nicholas J. Vogelzang, MD, talks about how MRI has improved the diagnosis of prostate cancer at Annual Meeting 2018.
Atrayee Basu Mallick, MD, shares her thoughts on the outcomes of the Checkmate 142 study looking ipilimumab and nivolumab in…
Ivo Abraham, PhD, RN, shares his perspective on biosimilar pricing and reimbursement at Annual Meeting 2018.
Mohammad Jahanzeb, MD, FACP, explains what he might do in sequencing therapies as a result of Keynote 189 and Keynote…
John Leighton, MD, shares the outcomes of the Checkmate 142 study examining ipilimumab and nivolumab in metastatic colorectal cancer (mCRC)…
Nicholas J. Vogelzang, MD, explains explains how to avoid under-diagnosing & over-diagnosing prostate cancer at Annual Meeting 2018.
Randall A. Oyer, MD, explains how ACCC is utilizing the data on genetics presented at the 2018 Annual Meeting Annual…
Atrayee Basu Mallick, MD, talks about the patient type and setting where vemurafenib has been added to the NCCN guidelines…
Mark Levis, MD, PhD, explains the impact of measurable residual disease in the clinical outcomes of patients with relapsed or…
Mohammad Jahanzeb, MD, FACP, explains the significance of Keynote 42 from Annual Meeting 2018.
Ivo Abraham, PhD, RN, talks about biosimilars that are approved or close to approval at Annual Meeting 2018.
Ghassan Abou-Alfa, MD, MBA, explains the shortcomings of the RECIST study in measuring efficacy in hepatocellular carcinoma (HCC) patients at…
Monoclonal antibodies are an exciting theapeutic avenue for hematological cancers, including multiple myeloma (MM). Here, Niels van de Donk, MD,…
There are an increasing amount of promising targeted therapies being investigated for multiple myeloma (MM). In this interview, Niels van…
The clinical significance of smoldering multiple myeloma (MM) is, as of recently, becoming much more important, especially in those patients…
The discovery of mutational events in cancer are crucial to the development of efficacious targeted therapies. Here, Steven Treon, MD,…
Speaking from the 1st European Myeloma Network (EMN) Meeting 2018, held in Turin, Italy, Francesca Gay, MD, of the University…
The progression of multiple myeloma (MM) can be monitored by determing what stage a patient is at; most notably, the…
Relapse often leads to difficulties in MM treatment, as patients may have developed resistance to a previous therapy. While the…
The progression of multiple myeloma (MM) can be monitored by determing what stage a patient is at; most notably, the…
Although there is a lot known about Waldenströms macroglobulinemia (WM), there is little understanding of the wild-type and IgM-related disorders.…
Despite the constant research and drug development going on in the field of multiple myeloma (MM), a cure is still…
While the European Society for Medical Oncology (ESMO) provides guidelines for patient treatment after initial relapse, these are not always…
Robert Kyle, MD, of the Mayo Clinic, Rochester, MN, talks about examples of new therapies that are currently under development…
The therapeutic potential for Waldenströms macroglobulinemia (WM) is widening, with our growing understanding and knowledge of the genetics behind this…
Although multiple myeloma (MM) has been known to physicians since the 1840s, effective treatments were not developed until much later.…
Stephen Devereux, FRCP, FRCPath, PhD, of Kings College Hospital NHS Foundation Trust, London, UK gives his highlights from the the…
There has been a multitude of novel, exciting therapies within the field of chronic lymphocytic leukemia (CLL), explains Stephen Devereux,…
The tumor microenvironment is an important therapeutic consideration. Here, Stephen Devereux, FRCP, FRCPath, PhD, of Kings College Hospital NHS Foundation…
New genetic sequencing techniques could yield profound insights into disease progression in chronic lymphocytic leukemia (CLL). Niamh Appleby, MB, BAO,…
Speaking from the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, held in Liverpool, UK, Niamh Appleby, MB, BAO,…
The 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, proved to be an exciting…
Atrayee Basu Mallick, MD, shares how how nivolumab is being incorporated into metastatic colorectal cancer (mCRC) treatment algorithms at Annual…
Mark Levis, MD, PhD, explains the key factors influencing 1st line therapy in acute myeloid leukemia(AML) patients with FLT3 mutations…
Mohammad Jahanzeb, MD, FACP, shares his thoughts on the continuation of pemetrexed maintenance after treatment of the patient with carboplatin,…
Jennie Crews, MD, MMM, FACP, talks about key initiatives for the ACCC Immuno-Oncology Institute at Annual Meeting 2018
Ghassan Abou-Alfa, MD, MBA, explains the outcomes of the CELESTIAL study from Annual Meeting 2018.
Atrayee Basu Mallick, MD, shares her thoughts on immunotherapy in colorectal cancer at Annual Meeting 2018.
Mark Levis, MD, PhD, explains the the impact of next-generation sequencing in AML at Annual Meeting 2018.
Mohammad Jahanzeb, MD, FACP, explains the results of Keynote 189, PDL-1 expression and patient selection at Annual Meeting 2018.
David R. Gandara, MD, talks about the benefits of using Cyramza® (ramucirumab) plus docetaxel verus docetaxel alone in 2nd line…
Ivo Abraham, PhD, RN, shares his thoughts on demonstrating the value of cancer care in today’s oncology landscape at Annual…
Jennie Crews, MD, MMM, FACP, discusses the mission of the ACCC Immuno-Oncology Institute at Annual Meeting 2018.
Ghassan Abou-Alfa, MD, MBA, explains how immunotherapies should be combined with TKIs at Annual Meeting 2018.
David R. Gandara, MD, explains drug sequencing as a result of Keynote 189 and 42 results at Annual Meeting 2018.
Tomasz M. Beer, MD, explains how immunotherapy is being integrated into CRPC treatment algorithms at Annual Meeting 2018.
Ivo Abraham, PhD, RN, explains the key characteristics of a biosimilar at Annual Meeting 2018.
Jennie Crews, MD, MMM, FACP, talks about how community oncology is interpreting and incorporating biomarkers into their immuno-oncology therapeutic choices
Ghassan Abou-Alfa, MD, MBA, talks about the latest in systemic therapy for advanced hepatocellular carcinoma (HCC) at the 2018 Annual…
Sara M. Tolaney, MD, MPH, talks about whether the results of the TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene…
Tomasz M. Beer, MD, explains how immunotherapy is being integrated into CRPC treatment algorithms at Annual Meeting 2018.
Joan Schiller, MD, talks about the Keynote trials presented and whether they will impact her choice of therapy for squamous…
David R. Gandara, MD, explains what will change about patient selection as a result of Keynote 42 at Annual Meeting…
Sara M. Tolaney, MD, MPH, talks about the TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene recurrence score patients, means…
Jeanny B. Aragon-Ching, MD, FACP, share the impact of the PROSPER and SPARTAN clinical trials at Annual Meeting 2018.
Although clinical trials provide us with an abundance of useful data, some of this may not be optimal for application…
Mick Peake, MD, of the University of Leicester, Leicester, UK, discusses the Collaboration for Oncology Data in Europe (CODE); an…
In this video, Mick Peake, MD, of the University of Leicester, Leicester, UK, notes the importance of collating information regarding…
Tomasz M. Beer, MD, explains how immunotherapy is being integrated into CRPC treatment algorithms at Annual Meeting 2018.
Roy S. Herbst, MD, PhD, explains the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC at Annual Meeting…
David R. Gandara, MD, talks about continuing pemextrexed maintenance
Jeanny B. Aragon-Ching, MD, FACP, discusses the 2nd line treatment options in RCC after I-O failure at Annual Meeting 2018.
Tomasz M. Beer, MD, talks about how the the PROSPER (enzalutamide) and SPARTAN (apalutamide) studies in non-metastatic castrate-resistant prostate cancer…
Sara M. Tolaney, MD, MPH, the fulvestrant + ribociclib arm of the MONALEESA-3 study
Joan Schiller, MD, shares the validity of Tumor Mutation Burden (TMB) as a biomarker at Annual Meeting 2018.
Roy S. Herbst, MD, PhD, talks about drug sequencing as a result of Keynote 189 and 42 results at Annual…
Jeanny B. Aragon-Ching, MD, FACP, discusses how checkpoint inhibitors figure into the treatment algorithms for unresectable 1st line renal cell…
Tomasz M. Beer, MD, discusses the latest trends in the multimodality treatment of prostate cancer at Annual Meeting 2018.
David R. Gandara, MD, explains whether Keynote 189 impacted view of PDL-1 expression and patient selection at Annual Meeting 2018.
Joan Schiller, MD, shares Keynote trials & the influence on choice of therapy from Annual Meeting 2018.
Sara M. Tolaney, MD, MPH, talks about whether CDK4/6 inhibitors can be used interchangeably at Annual Meeting 2018.
Robert A. Figlin, MD, explains the convenience factor of oral TKIs & treatment decisions in advanced RCC
Celestia S. Higano, MD, shares new data being presented for metastatic CRPC at Annual Meeting 2018.
Roy S. Herbst, MD, PhD, discusses if patient selection will change as a result of Keynote 42
Jeanny B. Aragon-Ching, MD, FACP, explains reliable molecular markers that can help identify high-risk muscle-invasive bladder cancer patients who should…
Tomasz M. Beer, MD, explains how to avoid under diagnosing and over diagnosing prostate cancer
David R. Gandara, MD, shares exciting new developments in lung cancer
Sara M. Tolaney, MD, MPH shares the MONARCH 2 study in pre and peri-menopausal ER+, HER2- breast cancer patients
Gary D. Steinberg, MD, explains whether FGFR inhibitors in metastatic bladder cancer have the potential to be practice changing.
Tomasz M. Beer, MD, explains the central themes regarding prostate cancer.
Jeanny B. Aragon-Ching, MD, FACP, discusses how new guidelines have changed the treatment of advanced metastatic bladder cancer.
Roy S. Herbst, MD, PhD, shares his thoughts on whether to continue pemetrexed maintenance after successful treatment of the patient…
Celestia S. Higano, MD, shares her thoughts on how immunotherapy is currently being integrated into castrate resistant prostate cancer treatment…
Edgardo S. Santos, MD, FACP, explains the benefits of docetaxel plus ramucirumab versus docetaxel alone during 2nd line non-small cell…
Joan Schiller, MD, shares her thoughts regarding the results of Keynote 42 presented at the 2018 Annual Meeting and how…
Treatment options for gynecological cancers have become more effective and diverse in the last few decades. In this video, Marcia…
Only a small minority of prostate cancer patients benefit from immunotherapy. Gerhardt Attard, MD, PhD, FRCP, of the Royal Marsden…
Speaking at the UK Oncology Forum (OF) 2018, held in Liverpool, UK, Dr Woolmore, Initiative Lead, Collaboration for Oncology Data…
Immunotherapy has huge potential for treating a wide variety of cancer types. In this video, recorded at the UK Oncology…
The RANGO project aims to create a database for rare gynecological tumors in order to facilitate improved disease understanding and…
The molecular signatures of tumor cells are often used to select patients for clinical trial recruitment. In this video, Gerhardt…
Much of the focus for immunotherapy research is on the cancers for which it works best, such as Hodgkin lymphoma…
Collaboration for Oncology Data in Europe (CODE) is a collaborative network that aims to promote the sharing of research data…
Measurable residual disease (MRD) is gaining traction not only as a prognostic indicator, but also as a tool for informing…
Quality of life and symptom data are essential for informing treatment plans as a clinician, as Esther Oliva, MD, of…
CAR T-cell therapy has been established as an effective treatment option for a range of hematological cancers. In this video,…
The drive to find treatment options for chronic lymphocytic leukemia (CLL) with lower toxicities means clinicians are relying less and…
Paolo Ghia, MD, of the Università Vita-Salute San Raffaele, Milan, presented preliminary data from the Phase II CAPTIVATE trial (NCT02910583)…
Social media has become increasingly relevant in the field of healthcare, both from the perspective of patients seeking the newest…
Iron-deficiency anemia is an extremely common form of anemia. Here, Maria Domenica Cappellini, MD, of the University of Milan-Foundation IRCCS…
While treatment for follicular lymphoma (FL) has improved in recent years, allowing most patients to have good outcomes, there remains…
Chronic lymphocytic leukemia (CLL) is usually fairly non-aggressive; however, there remain certain patients who have a rapidly progressing disease and…
Phase III trials EMN441 (NCT01091831) and EMN01 (NCT01093196) both investigated progression-free survival (PFS), overall survival (OS) and time to next…
Fabio Guolo, MD, of the University of Genoa, Genoa, Italy, spoke to us at the 23rd Congress of the European…
There are several genetic instruments available to measure the impact of Gaucher Disease (GD) on a patients quality of life,…
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, David Marks, MBBS, PhD,…
There are currently no concrete guidelines for how to use measurable residual disease (MRD) status to inform treatment decisions in…
Measurable residual disease (MRD) is arguably the most useful single prognostic tool we have within the field of acute lymphoblastic…
The RELEVANCE study (NCT01476787) looks at the ‘R-squared’ regimen that combines lenalidomide and rituximab for the treatment of follicular lymphoma.…
The management of relapsed chronic lymphocytic leukemia (CLL) is a complex and difficult issue. We interviewed William Wierda, MD, PhD,…
In this video, Raul Cordoba, MD, PhD, outlines the pre-clinical studies that are occurring at the Fundacion Jimenez Diaz University…
Biomarker screening has become an essential component of constructing treatment plans in chronic lymphocytic leukemia (CLL). In this video, recorded…
Eliminating high toxicity, invasive treatments like chemotherapy and stem cell transplant is a goal of acute lymphoblastic leukemia (ALL) research.…
Overexpression of CD123 is associated with a number of hematological malignancies, including myelofibrosis and chronic myelomonocytic leukemia (CMML). Data was…
There has been an influx of novel agents in the field of chronic lymphocytic leukemia (CLL) in recent years. These…
Thalassemia is caused by defects in either ? or ? globin chains, which are required for formation of functional hemoglobin…
The selective proteasome inhibitor carfilzomib has previously shown efficacy in terms of progression-free survival (PFS) for relapsed multiple myeloma (MM).…
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, John Seymour, MBBS, FRACP,…
The 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, saw many researchers reporting their most…
Although treatments for multiple myeloma (MM) are constantly improving, ~25% of patients still have poor outlooks. We spoke to Guy…
BCL-2 inhibitors like ibrutinib and venetoclax have been used in the treatment of lymphoproliferative disorders like chronic lymphocytic leukemia (CLL)…
The prognosis for patients with relapsed/refractory multiple myeloma (MM) is usually poor. In this video, Francesca Gay, MD, from the…
MOR208 is an anti-CD19 monoclonal antibody that has been effective in treating a range of lymphomas, including diffuse large B-cell…
There are promising results from a variety of studies implicating CAR T-cells in relapsed/refractory acute lymphoblastic leukemia (ALL) treatment. Here,…
Measurable residual disease (MRD) is becoming increasingly important as a prognostic indicator in a wide variety of hematological malignancies. We…
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Fabio Guolo, MD, of…
Treatments for low-risk myelodysplastic syndromes (MDS) cannot cure the disease, but rather aim to improve quality of life, reduce complications…
Idiopathic thrombocytopenic purpura or immune thrombocytopenia (ITP) is a disorder which may result in excessive bleeding or bruising due to…
The development of novel agents for treating chronic lymphocytic leukemia (CLL) has transformed the field in recent years. In this…
Inotuzumab ozogamicin has shown extremely promising results in clinical trials for treatment of relapsed/refractory acute lymphoblastic leukemia (ALL). There are,…
The development of novel agents to treat acute myeloid leukemia (AML) is constantly revolutionizing the field. In this video, Christoph…
Measurable residual disease (MRD) is used as a prognostic indictor in a variety of hematological maliganancies, including multiple myeloma (MM).…
We should move away from using risk factors as individual binary variables within acute lymphoblastic leukemia (ALL) research, suggests Anthony…
The European Hematology Association (EHA) Scientific Working Group on Aging and Hematology released a new edition about geriatric oncology. Here,…
Paolo Ghia, MD, of the Università Vita-Salute San Raffaele, Milan, Italy, is the president of the European Research Initiative on…
The use of tyrosine kinase inhibitors (TKIs) in chronic lymphocytic leukemia (CLL) is expanding. In this video, recorded at the…
Blastic plasmocytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy typically associated with poor patient outcomes. Naveen Pemmaraju, MD,…
The CLL11 trial (NCT01998880) compared chlorambucil monotherapy with combination therapies of chlorambucil and anti-CD20 antibodies rituximab or obinutuzumab for chronic…
Transfusion-dependent thalassemia demands regular and time-consuming treatment, with patients requiring blood transfusions every few weeks, and for the iron that…
Novel agent combination therapies are coming to the forefront of chronic lymphocytic leukemia (CLL) research. Here, William Wierda, MD, PhD,…
The RVD chemotherapy regimen combines lenalidomide, bortezomib, and dexamethasone, and is recognized by the European Society for Medical Oncology in…
MURANO (NCT02005471) is a Phase III randomized trial comparing the efficacy of venetoclax plus rituximab vs. standard chemoimmunotherapy of bendamustine…
Hareth Nahi, MD, of the Karolinska Institutet, Stockholm, Sweden, discusses the association between drug cost and toxicity at the 23rd…
The field of multiple myeloma (MM) has seen an influx of exciting new therapies. Here, Guy Pratt, MD, FRCP, FRCPath,…
In this interview at the 23rd Congress of European Haematology Association (EHA) 2018, held in Stockholm, Sweden, Gareth Morgan, MD,…
Lymphoproliferative disorders can be characterized by a certain set of pathogenic events. These include the upregulation of anti-apoptotic pathways guided…